Overview of the First 6 Months of Clinical Trials for COVID-19 Pharmacotherapy: The Most Studied DrugsCOVID-19 약물 요법에 대한 첫 6개월간의 임상 시험 개요: 가장 많이 연구된 약물Review Published on 2020-08-212022-09-11 Journal: Frontiers in Public Health [Category] 임상, [키워드] affecting Analysis Azithromycin Biology candidate drug candidate drugs China Chloroquine clinical clinical trial clinical trial (2.172) clinical trials conditions coronavirus (2019-nCoV) COVID-19 COVID-19 (condition) COVID-19 infection defined Diagnosis drug drugs duplication duplications effective therapy Effectiveness Epidemiology excessive immune response focus global effort global efforts Host Hydroxychloroquine identify include information Ivermectin Lopinavir management Month MOST other conditions pandemic Perspective representing Ritonavir SARS-CoV-2 Spread tested therapy Tocilizumab treat Treatment Vaccine virus WHO [DOI] 10.3389/fpubh.2020.00497 PMC 바로가기 [Article Type] Review
Ecotoxic response of nematodes to ivermectin, a potential anti-COVID-19 drug treatmentResearch article Published on 2020-08-012022-10-05 Journal: Marine pollution bulletin [Category] SARS, 치료법, [키워드] caused COVID-19 Diversity doses Ecotoxicity European France functional Italy Ivermectin ivermectin dose Meiobenthic nematodes nematode predict reduction in response Spain Treatment Trophic [DOI] 10.1016/j.marpolbul.2020.111375 [Article Type] Research article
Treatment Options for COVID-19: A ReviewMedicine Published on 2020-07-312022-10-31 Journal: Frontiers in Medicine [Category] COVID-19, [키워드] acute respiratory syndrome analyses antimicrobial agent antimicrobial agents Antiviral antiviral agent caused chloroquine/hydroxychloroquine coronavirus COVID-19 COVID-19 pandemic detect disease Drug repurposing effective Efficacy Evidence global pandemic globe Google Scholar higher infectivity highlight identify Immunoglobulin in vitro study Ivermectin lower mortality MERS-CoV morbidity and mortality multicenter option outbreak pandemic Pandemics Randomized controlled trial regimen Remdesivir retrospective review SARS-CoV SARS-CoV-2 searched single antiviral agent Tocilizumab Treatment Trial Vaccine virus widespread [DOI] 10.3389/fmed.2020.00480 PMC 바로가기 [Article Type] Medicine
Cellular and Molecular Pathways of COVID-19 and Potential Points of Therapeutic InterventionPharmacology Published on 2020-07-292022-10-31 Journal: Frontiers in Pharmacology [Category] COVID-19, [키워드] ACE2 Alpha alveolar cell antagonists Apoptosis AT1 biological marker blockade blockers capillary leakage CDK9 Cell cellular and molecular chemotactic clinical feature clinical marker contribute COVID-19 COVID-19 immune response CRP cytokine release Cytokine storm Cytokines cytoplasmic Defense Degradation Dexamethasone differentiation Diffuse alveolar damage downstream signaling pathway doxycycline element elevated elevated lactate dehydrogenase entry of SARS-CoV-2 epithelial estrogen receptor expression IL-17 IL-6 immune immune response Immunity include infiltration Inflammatory Inflammatory cytokine inflammatory cytokine production inflammatory signaling inhibitor initial Injury interferon response Intervention Ivermectin Jak kinase inhibitors LDH lung tissue MAPK mechanism melatonin membrane fusion membrane-bound molecular monocyte monocyte-derived macrophage NETosis NETs neutrophil Neutrophil extracellular trap Neutrophil-to-lymphocyte ratio NF-κB NLR p65 pathogenic pathophysiology pathway Platelet Pneumocytes Point Potential pro-inflammatory promote Prophylaxis provoke receptor reduce Remdesivir Research respiratory epithelia respiratory epithelial cells SARS-CoV-2 coronavirus selective Signal transduction skewed subtype T-cell therapeutic interventions therapeutic response Therapeutics thrombosis TNF-α type I interferons type III Vascular Viral load virus [DOI] 10.3389/fphar.2020.01169 PMC 바로가기 [Article Type] Pharmacology
Ivermectin: Potential Role as Repurposed Drug for COVID-19Brief Communications Published on 2020-07-192022-10-30 Journal: The Malaysian Journal of Medical Sciences : MJMS [Category] COVID-19, [키워드] 2019 novel coronavirus 2019-nCoV acute respiratory illness acute respiratory syndrome antibody antiparasitic approach being caused communicable coronavirus coronavirus disease Coronavirus disease 2019 country COVID-19 develop disease drug Drug repurposing effective effort information Ivermectin lack pandemic Pathogenesis pathway Potential proliferation rapid response Repurposed drug role SARS-CoV-2 spread to the disease therapeutic therapeutic agents therapeutic drug therapeutic option this new coronavirus Treatment Vaccine virus WHO World Health Organization [DOI] 10.21315/mjms2020.27.4.15 PMC 바로가기 [Article Type] Brief Communications
Safety, Pharmacokinetics, and Activity of High-Dose Ivermectin and Chloroquine against the Liver Stage of Plasmodium cynomolgi Infection in Rhesus Macaques붉은 털 원숭이에서 플라스 모디움 시노 몰기 감염의 간 단계에 대한 고용량 이베르세넥틴 및 클로로퀸의 안전성, 약동학 및 활동Pharmacology Published on 2020-07-132022-10-27 Journal: Antimicrobial Agents and Chemotherapy [Category] COVID-19, 말라리아, [키워드] activity acute respiratory syndrome Administered administration adverse event Bioavailability Chloroquine Combination coronavirus COVID-19 COVID-19 infections demonstrated dosed drug-drug interaction Efficacy evaluate evaluated hepatocyte High dose Human in vitro inhibit inhibitory concentration Ivermectin ivermectin dose liver macaque mice pharmacokinetic pharmacokinetics Plasmodium Plasmodium vivax prophylactically Prophylaxis Replication rhesus macaques Safety SARS-CoV-2 shown Stage therapy Trial [DOI] 10.1128/AAC.00741-20 PMC 바로가기 [Article Type] Pharmacology
Pandemic COVID-19: Current status and challenges of antiviral therapiesArticle Published on 2020-07-072023-08-30 Journal: Genes & Diseases [Category] E형 간염, [키워드] Chloroquine Convalescent plasma therapy COVID-19 Hydroxychloroquine Ivermectin Natural killer cell therapy Remdesivir SARS-CoV-2 [DOI] 10.1016/j.gendis.2020.07.001 PMC 바로가기
Turning the Tide: Natural Products and Natural-Product-Inspired Chemicals as Potential Counters to SARS-CoV-2 InfectionPharmacology Published on 2020-07-022022-10-31 Journal: Frontiers in Pharmacology [Category] COVID-19, [키워드] acute respiratory syndrome anti-SARS-CoV-2 antiviral activities Antiviral agents cause Chemical coronavirus coronavirus disease counter COVID-19 drug Ebselen effective EIDD-2801 GS-5734 highly pathogenic homoharringtonine Ivermectin natural natural products natural-product-inspired Potential potential anti-SARSCoV-2 agents product public health Research Safe SARS-CoV-2 SARS-COV-2 infection small molecule Turning [DOI] 10.3389/fphar.2020.01013 PMC 바로가기 [Article Type] Pharmacology
The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trialLetter Published on 2020-06-082022-10-29 Journal: Trials [Category] COVID-19, SARS, [키워드] 1:1 48 hour 48 hours Activation Administered adverse event African age allergy analyzed Angola Antiviral approved ARMS Barcelona baseline blinded block Cerebrovascular disease chain chest X-ray childbearing chronic clinical care clinical trial co-morbidity conducted contraceptive method control group coronary disease cough country COVID-19 COVID-19 disease COVID-19 patient criteria Critical current CYP3A4 death detectable determine diagnosed with COVID-19 disease dissemination dose double-blind drug early treatment Efficacy element Endemic EudraCT excluded eye Factor Fever flow cytometry Follow-up visit Frequency Gabon global health groups history home visit Identified IgA IgA level IgG IgM immune response Immunity immunology immunomodulatory IMPROVE in vivo Infection Inflammatory inhibitor interfere investigator involved Isolation Ivermectin laboratory parameter Loa loa magnitude marker median Nasopharyngeal swab nasopharyngeal swab PCR negative neoplasm Nigeria no risk number objective outcome participant Patient Patient care patients PCR PCR cycle physical Placebo placebo group placebo-controlled Pneumonia positive positive SARS-CoV-2 PCR post-menopausal Potential pregnancy test pregnant women progression proportion protocol public health pulmonary random randomised randomised controlled trial randomization randomization list Randomized Rapid diagnostic test reaction receive recent recruited reduce Registered renal resident risk Ritonavir Safe Sample size SARS-CoV-2 SARS-CoV-2 RNA SARS-CoV-2-specific T cell secondary sequence Seroconversion severe disease severity single center single dose Spain status Study protocol subject submitted surgical Symptom symptom onset the patient the SARS-CoV-2 threshold transcriptomics Transmission transmission-blocking Travel treated patient treated patients Treatment treatment group Trial unblinding Viral load virus vulnerable population website with mild disease women [DOI] 10.1186/s13063-020-04421-z PMC 바로가기 [Article Type] Letter
An overview on COVID-19: reality and expectationReview Published on 2020-06-012022-10-28 Journal: Bulletin of the National Research Centre [Category] COVID-19, [키워드] absence acute respiratory syndrome approved blood pressure Care China Chloroquine clinically comprehensive view coronavirus COVID-19 COVID-19 outbreak detect diabetes Disease diagnosis drug Drug discovery drugs effective emergency situation Favipiravir Herbal treatment Hydroxychloroquine incidence of COVID-19 Infection International Ivermectin Liver disease measure Medical conditions Messenger RNA National obesity other disease Patient Plasma transfusion polymerase chain Prevent progression public health reduce Remdesivir ribavirin risk RT-PCR SARS-CoV-2 Spread susceptible tested treat Treatment Vaccine vaccine candidate Vaccine development Vaccines viral outbreak virus WHO WHO’ [DOI] 10.1186/s42269-020-00341-9 PMC 바로가기 [Article Type] Review